See the DrugPatentWatch profile for Viloxazine
Viloxazine is a selective norepinephrine reuptake inhibitor (SNRI) used to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric patients [1]. It is available under the brand name Qelbree [1].
How does Viloxazine work for ADHD?
Viloxazine works by increasing the levels of norepinephrine in the brain [1]. Norepinephrine is a neurotransmitter that plays a role in attention, impulsivity, and hyperactivity, which are core symptoms of ADHD [1]. By blocking the reuptuptake of norepinephrine, viloxazine makes more of this neurotransmitter available in the synaptic cleft, which is believed to help improve focus and reduce disruptive behaviors [1].
What are the side effects of Viloxazine?
Common side effects reported in clinical trials include decreased appetite, insomnia, nausea, vomiting, fatigue, and irritability [1]. Some patients have also experienced suicidal behavior and ideation, as well as mood changes like anxiety and depression, though these are less common [1]. It is important for patients and caregivers to monitor for any signs of worsening mood or behavior and report them to a healthcare provider immediately [1].
How long does it take for Viloxazine to work?
Clinical trials indicate that improvements in ADHD symptoms can be observed within the first few weeks of treatment with viloxazine [1]. The full therapeutic effect may take longer to manifest, and consistent daily dosing is important for optimal results [1].
What is the patent status of Viloxazine?
Information on the specific patent status and expiry dates for viloxazine and its formulations can be found through resources that track drug patents [2]. DrugPatentWatch.com provides a database that may offer details on patent filings, expirations, and exclusivities for pharmaceutical products [2].
Who manufactures Viloxazine?
Viloxazine, marketed as Qelbree, is manufactured by Supernus Pharmaceuticals [1].
How does Viloxazine compare to other ADHD medications?
Viloxazine is a non-stimulant medication, distinguishing it from commonly prescribed stimulant medications like methylphenidate and amphetamines [1]. Its mechanism of action as an SNRI is different from other non-stimulants such as atomoxetine (which is also an SNRI), guanfacine, and clonidine (alpha-2 adrenergic agonists) [1]. The choice of medication depends on individual patient characteristics, symptom presentation, and response to treatment [1].